Clinical Trials · NCT02973321
A Study to Assess the Safety and Efficacy of SAR425899 in Patients With Type 2 Diabetes Mellitus
- Phase
- Phase 2
- Recruitment status
- Completed
- Sponsor
- Sanofi
- Enrollment
- 296
- Start date
- Dec 2016
- Locations
- 59 sites, 8 countries
- Primary endpoint
- Change From Baseline in HbA1c to Week 26